NCT03876769: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
- State
- Under way
- Phase
- Phase 2
- People
- 121 taking part
- Started
- 24 Jun 2019
- Primary completion
- 19 Oct 2027
- Arms
- Single dose of CTL019
- Results
- None posted
- 15 Mar 2019: Trial registered
- 24 Jun 2019: Trial started